{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:02:03Z","timestamp":1775790123386,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12288-021-01430-z","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T07:04:53Z","timestamp":1617260693000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of HIDAC 18\u00a0g Versus IDAC 9\u00a0g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Dinesh","family":"Ravikumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honey","family":"Saju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Choudary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7377","authenticated-orcid":false,"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"1430_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3324\/haematol.2014.114611","volume":"99","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF (2014) Post-remission therapy for acute myeloid leukemia. Haematologica 99:1663\u20131670","journal-title":"Haematologica"},{"key":"1430_CR2","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","volume":"29","author":"M Schaich","year":"2011","unstructured":"Schaich M, R\u00f6llig C, Soucek S et al (2011) Cytarabine dose of 36 g\/m2 compared with 12 g\/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol Off J Am Soc Clin Oncol 29:2696\u20132702","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1430_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"1430_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00277-012-1436-z","volume":"91","author":"M Hengeveld","year":"2012","unstructured":"Hengeveld M, Suciu S, Karrasch M et al (2012) Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto (GIMEMA) Leukemia Cooperative Groups. Ann Hematol 91:825\u2013835","journal-title":"Ann Hematol"},{"key":"1430_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","volume":"106","author":"MS Tallman","year":"2005","unstructured":"Tallman MS, Gilliland DG, Rowe JM (2005) Drug therapy for acute myeloid leukemia. Blood 106:1154\u20131163","journal-title":"Blood"},{"key":"1430_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-2141.2006.06314.x","volume":"135","author":"DW Milligan","year":"2006","unstructured":"Milligan DW, Grimwade D, Cullis JO et al (2006) Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 135:450\u2013474","journal-title":"Br J Haematol"},{"key":"1430_CR7","first-page":"993","volume":"17","author":"S Keating","year":"1996","unstructured":"Keating S, Suciu S, de Witte T et al (1996) Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell\u2019 Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transpl 17:993\u20131001","journal-title":"Bone Marrow Transpl"},{"key":"1430_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896\u2013903","journal-title":"N Engl J Med"},{"key":"1430_CR9","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-04-0185","volume":"10","author":"WR Sperr","year":"2004","unstructured":"Sperr WR, Piribauer M, Wimazal F et al (2004) A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 \u00d7 1 g\/m2 on days 1, 3, and 5). Clin Cancer Res 10:3965\u20133971","journal-title":"Clin Cancer Res"},{"key":"1430_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2141.1984.tb02898.x","volume":"57","author":"HC van Prooijen","year":"1984","unstructured":"van Prooijen HC, Dekker AW, Punt K (1984) The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol 57:291\u2013299","journal-title":"Br J Haematol"},{"key":"1430_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","volume":"121","author":"B L\u00f6wenberg","year":"2013","unstructured":"L\u00f6wenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121:26\u201328","journal-title":"Blood"},{"key":"1430_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1008267904952","volume":"8","author":"M Fopp","year":"1997","unstructured":"Fopp M, Fey MF, Bacchi M et al (1997) Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Ann Oncol 8:251\u2013257","journal-title":"Ann Oncol"},{"key":"1430_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajh.25484","volume":"94","author":"BC Medeiros","year":"2019","unstructured":"Medeiros BC, Chan SM, Daver NG et al (2019) Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol 94:803\u2013811","journal-title":"Am J Hematol"},{"key":"1430_CR14","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 117:2366\u20132372","journal-title":"Blood"},{"key":"1430_CR15","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1038\/bcj.2017.45","volume":"7","author":"S Jaramillo","year":"2017","unstructured":"Jaramillo S, Benner A, Krauter J et al (2017) Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J 7:e564","journal-title":"Blood Cancer J"},{"key":"1430_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bjh.13406","volume":"170","author":"C Philip","year":"2015","unstructured":"Philip C, George B, Ganapule A et al (2015) Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 170:110\u2013117","journal-title":"Br J Haematol"},{"key":"1430_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1155\/2013\/582569","volume":"35","author":"PS Chauhan","year":"2013","unstructured":"Chauhan PS, Ihsan R, Singh LC et al (2013) Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. Dis Markers 35:581\u2013588","journal-title":"Dis Markers"},{"key":"1430_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/ajco.12333","volume":"11","author":"A Bahl","year":"2015","unstructured":"Bahl A, Sharma A, Raina V et al (2015) Long-term outcomes for patients with acute myeloid leukemia: a single-center experience from AIIMS, India. Asia Pac J Clin Oncol 11:242\u2013252","journal-title":"Asia Pac J Clin Oncol"},{"key":"1430_CR19","unstructured":"Cancer Statistics Review, 1975\u20132014\u2014SEER Statistics. In: SEER. Accessed from: Leukemia, CSR 1975\u20132014 (cancer.gov)\u2014SEER Statistics on 10th October 2019."},{"key":"1430_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1055-9965.EPI-11-1087","volume":"21","author":"BM Craig","year":"2012","unstructured":"Craig BM, Rollison DE, List AF, Cogle CR (2012) Underreporting of myeloid malignancies by United States Cancer Registries. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 21:474\u2013481","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"1430_CR21","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","volume":"119","author":"G Juliusson","year":"2012","unstructured":"Juliusson G, Lazarevic V, H\u00f6rstedt A-S et al (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119:3890\u20133899","journal-title":"Blood"},{"issue":"10","key":"1430_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/ajh.25214","volume":"93","author":"EH Estey","year":"2018","unstructured":"Estey EH (2018) Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol 93(10):1267\u20131291","journal-title":"Am J Hematol"},{"key":"1430_CR23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1182\/blood-2011-04-349258","volume":"118","author":"X Thomas","year":"2011","unstructured":"Thomas X, Elhamri M, Raffoux E et al (2011) Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 118:1754\u20131762","journal-title":"Blood"},{"key":"1430_CR24","first-page":"643","volume":"32","author":"T Fukushima","year":"2012","unstructured":"Fukushima T, Urasaki Y, Yamaguchi M et al (2012) A randomized comparison of modified intermediate-dose Ara-C versus high-dose Ara-C in post-remission therapy for acute myeloid leukemia. Anticancer Res 32:643\u2013647","journal-title":"Anticancer Res"},{"key":"1430_CR25","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol Off J Am Soc Clin Oncol 31:3360\u20133368","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1430_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00277-015-2389-9","volume":"94","author":"DS Kim","year":"2015","unstructured":"Kim DS, Kang K-W, Lee SR et al (2015) Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Ann Hematol 94:1485\u20131492","journal-title":"Ann Hematol"},{"key":"1430_CR27","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1182\/blood.V128.22.4032.4032","volume":"128","author":"NA Abdul Halim","year":"2016","unstructured":"Abdul Halim NA, Wong GC, Aloysius HY et al (2016) High dose cytarabine is superior to intermediate dose cytarabine as post-remission therapy for younger patients with favorable risk acute myeloid leukemia. Blood 128:4032\u20134032","journal-title":"Blood"},{"key":"1430_CR28","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1182\/blood-2019-123306","volume":"134","author":"B Kolla","year":"2019","unstructured":"Kolla B, Halim NAA, Sachs Z et al (2019) High risk of relapse with intermediate dose cytarabine for consolidation in young favorable risk AML patients following induction with 7+3. Blood 134:3432\u20133432","journal-title":"Blood"},{"key":"1430_CR29","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1158\/1078-0432.CCR-19-3433","volume":"26","author":"H Wei","year":"2020","unstructured":"Wei H, Wang Y, Gale RP et al (2020) Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia. Clin Cancer Res 26:3154\u20133161","journal-title":"Clin Cancer Res"},{"key":"1430_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"D Wu","year":"2017","unstructured":"Wu D, Duan C, Chen L, Chen S (2017) Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Sci Rep 7:1\u201310","journal-title":"Sci Rep"},{"key":"1430_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12288-018-1023-0","volume":"35","author":"JP Kalaiyarasi","year":"2019","unstructured":"Kalaiyarasi JP, Ganesan P, Kannan K et al (2019) Outcomes of intensive treatment of adult acute myeloid leukemia patients: a retrospective study from a single centre. Indian J Hematol Blood Transfus 35:248\u2013254","journal-title":"Indian J Hematol Blood Transfus"},{"key":"1430_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2017-04-777722","volume":"130","author":"KN Magina","year":"2017","unstructured":"Magina KN, Pregartner G, Zebisch A et al (2017) Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood 130:946\u2013948","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-021-01430-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T09:31:20Z","timestamp":1643621480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-021-01430-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s12288-021-01430-z","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institute Ethics approval was taken before commencement of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Waiver of consent was granted for the retrospective data and analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}